{"title":"大流行后卫生:超国家影响和监管协调","authors":"Ximena Benavides Reverditto","doi":"10.1093/icon/moac116","DOIUrl":null,"url":null,"abstract":"\n The dominant position of the U.S. Food and Drug Administration (FDA) as the most influential regulator in the world has been particularly salient during the COVID-19 pandemic, in the context of COVID-19 vaccines’ emergency use authorizations. In the context of adjustment toward a post-COVID-19 regulatory order of harmonization for medicines approval, this essay proposes a critical reflection about the justifications and political dynamics behind the FDA’s power and its impact in latinamerican countries’ regulatory systems, considering the already regulatory reliance on the FDA. In particular, this essay asks whether regulatory ‘agility’ and ‘coordination’ will benefit countries of the region in addressing the problems of scarcity and inequitable access to medicines that have become evident with the pandemic.","PeriodicalId":51599,"journal":{"name":"Icon-International Journal of Constitutional Law","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2023-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Salud postpandemia: influencia supranacional y coordinación regulatoria\",\"authors\":\"Ximena Benavides Reverditto\",\"doi\":\"10.1093/icon/moac116\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n The dominant position of the U.S. Food and Drug Administration (FDA) as the most influential regulator in the world has been particularly salient during the COVID-19 pandemic, in the context of COVID-19 vaccines’ emergency use authorizations. In the context of adjustment toward a post-COVID-19 regulatory order of harmonization for medicines approval, this essay proposes a critical reflection about the justifications and political dynamics behind the FDA’s power and its impact in latinamerican countries’ regulatory systems, considering the already regulatory reliance on the FDA. In particular, this essay asks whether regulatory ‘agility’ and ‘coordination’ will benefit countries of the region in addressing the problems of scarcity and inequitable access to medicines that have become evident with the pandemic.\",\"PeriodicalId\":51599,\"journal\":{\"name\":\"Icon-International Journal of Constitutional Law\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2023-03-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Icon-International Journal of Constitutional Law\",\"FirstCategoryId\":\"90\",\"ListUrlMain\":\"https://doi.org/10.1093/icon/moac116\",\"RegionNum\":3,\"RegionCategory\":\"社会学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"LAW\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Icon-International Journal of Constitutional Law","FirstCategoryId":"90","ListUrlMain":"https://doi.org/10.1093/icon/moac116","RegionNum":3,"RegionCategory":"社会学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"LAW","Score":null,"Total":0}
Salud postpandemia: influencia supranacional y coordinación regulatoria
The dominant position of the U.S. Food and Drug Administration (FDA) as the most influential regulator in the world has been particularly salient during the COVID-19 pandemic, in the context of COVID-19 vaccines’ emergency use authorizations. In the context of adjustment toward a post-COVID-19 regulatory order of harmonization for medicines approval, this essay proposes a critical reflection about the justifications and political dynamics behind the FDA’s power and its impact in latinamerican countries’ regulatory systems, considering the already regulatory reliance on the FDA. In particular, this essay asks whether regulatory ‘agility’ and ‘coordination’ will benefit countries of the region in addressing the problems of scarcity and inequitable access to medicines that have become evident with the pandemic.